Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nobuaki Matsubara

Showing results (1-10 of 179) with videos related to

Pageof 18
Sort By:
Chinese Clinical Oncology|March 9, 2026
Patient-reported outcomes in TALAPRO-2 trial: addressing data integrity and comparative clinical benefit in mCRPCNobuaki Matsubara
Zoological Science|August 3, 2021
Possible Role of Polarized Light Information in Spatial Recognition in the Cricket <i>Gryllus bimaculatus</i>Nobuaki Matsubara, Ryuichi Okada, Midori Sakura
Oncology|January 18, 2012
Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancerNobuaki Matsubara, Hirofumi Mukai, Kuniaki Itoh, et al.
Journal of Chemotherapy (Florence, Italy)|September 9, 2025
A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancerNobuaki Matsubara, Koji Dozono, Karim Nacerddine, et al.
European Urology Open Science|January 31, 2022
Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE StudyYosuke Koroki, Masataka Taguri, Nobuaki Matsubara, et al.
International Journal of Clinical Oncology|October 8, 2011
Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 casesNobuaki Matsubara, Kuniaki Itoh, Hirofumi Mukai, et al.
International Journal of Clinical Oncology|August 12, 2010
Review of primary unknown cancer: cases referred to the National Cancer Center Hospital EastNobuaki Matsubara, Hirofumi Mukai, Shunji Nagai, et al.
Breast Cancer Research and Treatment|November 28, 2012
Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancerNobuaki Matsubara, Hirofumi Mukai, Satoshi Fujii, et al.
Asia-Pacific Journal of Clinical Oncology|November 7, 2012
Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancerNobuaki Matsubara, Hirofumi Mukai, Yoichi Naito, et al.
Japanese Journal of Clinical Oncology|July 31, 2019
Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance studyKazuhiro Suzuki, Nobuaki Matsubara, Hirotaka Kazama, et al.
Pageof 18

Showing results (1-10 of 179) with videos related to

Sort By:
Pageof 18
Chinese Clinical Oncology|March 9, 2026
Patient-reported outcomes in TALAPRO-2 trial: addressing data integrity and comparative clinical benefit in mCRPCNobuaki Matsubara
Zoological Science|August 3, 2021
Possible Role of Polarized Light Information in Spatial Recognition in the Cricket <i>Gryllus bimaculatus</i>Nobuaki Matsubara, Ryuichi Okada, Midori Sakura
Oncology|January 18, 2012
Prognostic impact of Ki-67 overexpression in subgroups categorized according to St. Gallen with early stage breast cancerNobuaki Matsubara, Hirofumi Mukai, Kuniaki Itoh, et al.
Journal of Chemotherapy (Florence, Italy)|September 9, 2025
A Phase 1 study of abemaciclib plus abiraterone in Japanese patients with metastatic castration-resistant prostate cancerNobuaki Matsubara, Koji Dozono, Karim Nacerddine, et al.
European Urology Open Science|January 31, 2022
Estimation of Overall Survival with Subsequent Treatment Effect by Applying Inverse Probability of Censoring Weighting in the LATITUDE StudyYosuke Koroki, Masataka Taguri, Nobuaki Matsubara, et al.
International Journal of Clinical Oncology|October 8, 2011
Long-term outcome of pleurodesis with OK-432 in metastatic breast cancer: a new risk model for success from an analysis of 75 casesNobuaki Matsubara, Kuniaki Itoh, Hirofumi Mukai, et al.
International Journal of Clinical Oncology|August 12, 2010
Review of primary unknown cancer: cases referred to the National Cancer Center Hospital EastNobuaki Matsubara, Hirofumi Mukai, Shunji Nagai, et al.
Breast Cancer Research and Treatment|November 28, 2012
Different prognostic significance of Ki-67 change between pre- and post-neoadjuvant chemotherapy in various subtypes of breast cancerNobuaki Matsubara, Hirofumi Mukai, Satoshi Fujii, et al.
Asia-Pacific Journal of Clinical Oncology|November 7, 2012
Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancerNobuaki Matsubara, Hirofumi Mukai, Yoichi Naito, et al.
Japanese Journal of Clinical Oncology|July 31, 2019
Safety and efficacy of cabazitaxel in 660 patients with metastatic castration-resistant prostate cancer in real-world settings: results of a Japanese post-marketing surveillance studyKazuhiro Suzuki, Nobuaki Matsubara, Hirotaka Kazama, et al.
Pageof 18